HMG-CoA Reductase Inhibitors Attenuate Neuronal Damage by Suppressing Oxygen Glucose Deprivation-Induced Activated Microglial Cells

Dan Lu, Lingling Shen, Hongcheng Mai, Jiankun Zang, Yanfang Liu, Chi-kwan Tsang, Keshen Li, and Anding Xu

1The First Affiliated Hospital, Jinan University, Guangzhou, China
2Department of Neurology and Stroke Center, The First Affiliated Hospital, Jinan University, Guangzhou, China
3Clinical Neuroscience Institute of Jinan University, Guangzhou, China

Correspondence should be addressed to Anding Xu; tlil@jnu.edu.cn

Dan Lu and Lingling Shen contributed equally to this work.

Received 17 April 2018; Revised 3 October 2018; Accepted 22 October 2018; Published 17 February 2019

Academic Editor: Long-Jun Wu

Copyright © 2019 Dan Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ischemic stroke is usually followed by inflammatory responses mediated by microglia. However, the effect of statins on directly preventing posthypoxia microglia inflammatory factors to prevent injury to surrounding healthy neurons is unclear. Atorvastatin and rosuvastatin, which have different physical properties regarding their lipid and water solubility, are the most common HMG-CoA reductase inhibitors (statins) and might directly block posthypoxia microglia inflammatory factors to prevent injury to surrounding neurons. Neuronal damage and microglial activation of the peri-infarct areas were investigated by Western blotting and immunofluorescence after 24 hours in a middle cerebral artery occlusion (MCAO) rat model. The decrease in neurons was in accordance with the increase in microglia, which could be reversed by both atorvastatin and rosuvastatin. The effects of statins on blocking secretions from posthypoxia microglia and reducing the secondary damage to surrounding normal neurons were studied in a coculture system in vitro. BV2 microglia were cultured under oxygen glucose deprivation (OGD) for 3 hours and then cocultured following reperfusion for 24 hours in the upper wells of transwell plates with primary neurons being cultured in the bottom wells. Inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and cyclooxygenase-2 (COX2), which are activated by the nuclear factor-kappa B (NF-κB) signaling pathway in OGD-induced BV2 microglia, promoted deceased release of the anti-inflammatory cytokine IL-10 and apoptosis of neurons in the coculture systems according to ELISA and Western blotting. However, pretreatment with atorvastatin or rosuvastatin significantly reduced neuronal death, synaptic injury, and amyloid-beta (Aβ) accumulation, which might lead to increased low-density lipoprotein receptors (LDLRs) in BV2 microglia. We concluded that the proinflammatory mediators released from postischemia damage could cause damage to surrounding normal neurons, while HMG-CoA reductase inhibitors prevented neuronal apoptosis and synaptic injury by inactivating microglia through blocking the NF-κB signaling pathway.

1. Introduction

Ischemic stroke, accounting for eighty percent of all strokes, is one of the most common diseases and a leading cause of death and disability worldwide [1–3]. It is usually followed by inflammatory responses mediated by microglia [4, 5]. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are traditional drugs widely used for secondary prevention of ischemic stroke by lowering lipids [6] and reducing inflammation [7, 8]. In addition, some studies have reported that pretreatment with HMG-CoA reductase inhibitors in animal stroke models [9] is effective for improving both short-term [10] and long-term functional outcomes in clinical trials [11].
However, how to inhibit the secondary and morphological injury of healthy neurons in the peri-infarct region must still be explored. While inflammation-induced hypoxia-ischemia neuronal damage has been previously reported [2, 12], the direct effect of secretions from microglia after cerebral ischemia on healthy neurons will be studied, which we believe may be a possible cause of penumbra formation. Actually, atorvastatin has no direct neuron protection effects [13], while rosuvastatin induces delayed preconditioning against oxygen-glucose deprivation in cultured cortical neurons [14]. That implies that the neuron loss inhibited by statins does not completely follow the same mechanism as that on neurons. According to the anti-inflammatory function of statins, we reason that the same mechanism of the common statins in neuroprotection under brain ischemia might be antineuroinflammation by inhibiting the secretion of microglia activation. This study will elucidate new targets for determining how the inhibition of microglial secretion by statin therapy can prevent deterioration of healthy neurons.

Microglia are the principal immune cells in the brain, representing a continuum of different phenotypes [15]. Therein, emerging studies have concentrated on the regulatory mechanisms that underlie the activation of microglia and have aimed at inhibiting the microglia activation to secrete proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and cyclooxygenase-2 (COX2) to inhibit secondary inflammation injury after ischemia in cells [16] and to facilitate protective microglia to secrete anti-inflammatory cytokines, such as IL-10, which my facilitate anti-inflammation, axonal outgrowth and promote neuron recovery [17, 18].

Statin therapy induces competitive inhibition of cholesterol synthesis by upregulating low-density lipoprotein receptors (LDLRs) and lowering low-density lipoprotein (LDL) in the peripheral blood system [19]. LDLR is a cell surface receptor of LDL and causes hypercholesteremia and risk of cardiovascular and cerebrovascular diseases, including cerebral stroke, by acting in the catabolism of LDL-C by endocytosis via clathrin-coated pits [19, 20]. Studies have shown that LDLR is also expressed in microglia and decreased expression of LDLR led to increased circulating LDL and neuroinflammation in Alzheimer’s disease models [21–23]. Recent studies have also discovered that modulation of LDLR may be a safe and efficient therapy for AD by accelerating amyloid-beta (Aβ) clearance to inhibit neuronal apoptosis [24, 25]. Vascular and neurodegenerative pathologies contribute to Aβ accumulation and cause further neurotoxicity due to proinflammation, apoptosis, and synaptic injury pathways [26–29]. The immune system may contribute to the outcome of infarction [30]. As a fact, the observation study showed that a high percentage of patients suffered from ischemic stroke subsequently to develop AD, which suggests that there is a strong link between the pathologies of stroke and AD. In addition, both hypoxia and ischemic injury increase the production of Aβ by hypoxia-inducible factor 1α (HIF1α) activating the increase of BACE1 expression [31], which further confirms the link between AD and stroke [32]. There is also evidence that HMG-CoA reductase inhibitors exert anti-inflammatory effects induced by Aβ [33].

Although statin therapy can induce anti-inflammatory effects in many nervous system diseases, the direct effect of statins on preventing posthypoxia microglial inflammatory factors to minimize injury to surrounding healthy neurons remains unclear. Thus, we investigated whether two common statins, atorvastatin and rosuvastatin, prevented secretion by posthypoxia microglia to block secondary damage to surrounding normal neurons in vitro. In clinical administration, prior statin treatment is associated with lower stroke severity and better outcomes in acute ischemic stroke patients and statin pretreatment in patients with acute large artery atherosclerosis appears to be associated with better early outcomes regarding neurologic improvement, disability, survival, and stroke recurrence [34].

2. Materials and Methods

2.1. Middle Cerebral Artery Occlusion (MCAO) Model. A total of 45 male Sprague Dawley rats (200–250 g) were purchased from Guangdong Medical Laboratory Animal Center, Guangzhou, China. Thirty-five rats were subjected to MCAO, and 10 rats served as sham-operated controls. The MCAO model was developed as previously described [35]. Briefly, the rats were anesthetized with 10% chloral hydrate (BBI Life Sciences, Shanghai, China, 300 μL/100 g) by intraperitoneal injection. The left middle cerebral artery was exposed through a subtemporal craniectomy and occluded by electrocoagulation under an operating microscope. Sham-operated animals underwent the same surgical procedures apart from electrocoagulation. Before operation, rats in the drug treatment and vehicle groups were intraperitoneally injected with rosuvastatin (Sigma, St. Louis, MO, USA, 5 mg/mL in normal saline, 5 mg/kg/d) or atorvastatin (Sigma, St. Louis, MO, USA, dissolved in DMSO and allyl injected with rosuvastatin (Sigma, St. Louis, MO, USA, 5 mg/mL in normal saline, 5 mg/kg/d) or atorvastatin (Sigma, St. Louis, MO, USA, dissolved in DMSO and isomolar vehicle for three days. The animal experimental protocols were approved by the Animal Care and Use Committee of Jinan University. All experimental protocols involving rats were approved by the ethical committee of Jinan University and performed in accordance with approved guidelines and regulations.

2.2. 2,3,5-Triphenyltetrazolium Chloride (TTC) Staining. Five MCAO rats were deeply anesthetized with 10% chloral hydrate (600 μL/100 g). The brains were quickly removed and chilled at -20°C for 20 min; the frozen brains were then coronally sliced into six sections (2 mm-thick sections). The sections were stained with 2% TTC (BBI Life Sciences, Shanghai, China) at 37°C for 30 min and fixed in 4% paraformaldehyde for 24 hours at 4°C. The stained slides were photographed using a camera (Leica, Heidelberg, Germany).

2.3. Cell Culture and Oxygen-Glucose Deprivation/Reperfusion (OGD) Model. Immortal BV2 murine microglial cells exhibit the phagocytosis and inflammatory activation characteristics of microglia [36]. For BV2 microglia culture, BV2 cells were
incubated in the upper wells of 6-well transwell plates (40000/well) in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, New York, USA) with 10% foetal bovine serum (FBS) (Biological Industries, CT, USA) for 24 hours at 37°C in a 5% CO₂ incubator.

For the OGD experiments, cells were incubated in Hank’s buffer and placed in an oxygen-free culture induced by a hermetic bag and AnaeroPac-Anaero (Mitsubishi Gas Chemical, Tokyo, Japan) for 3 hours at 37°C. The cells were then reperfused and reincubated with DMEM with 10% FBS for 24 hours at 37°C in a 5% CO₂ incubator.

For primary neuron culture, dissociated primary neurons of the cerebral cortex were collected from new-born mice within 12 hours of birth. Primary cortical neurons were incubated in the bottom wells of 6-well transwell plates (Corning, New York, USA) in DMEM/F12 (Gibco, New York, USA) for 4 hours at 37°C in a 5% CO₂ incubator. The medium was then changed to neurobasal medium (Gibco, New York, USA) with 2% B27 (Gibco, New York, USA) and incubated for another 6 days at 37°C in a 5% CO₂ incubator.

To study the effect of microglia secretion on neurons, coculture systems were set up as follows. After OGD for 3 hours and subsequent reperfusion for 24 hours at 37°C in a 5% CO₂ incubator, hypoxic BV2 cells were carefully placed in the upper wells of 6-well transwell plates and cocultured with primary neurons in the bottom wells (Figure 1(c)).

2.4. Cell Viability Assays. The cell viability of BV2 cells was determined using methylthiazolyldiphenyl-tetrazolium (MTT) assays. A total of 5000 BV2 cells/well were incubated in 96-well plates in DMEM with 10% FBS for 12 hours at 37°C in a 5% CO₂ incubator. Before inducing OGD, BV2 cells were pretreated with different doses of atorvastatin (0.1, 0.5, 1, and 2 μM and the isomolar DMSO vehicle) or rosuvastatin (0, 0.5, 1, 5, 10, and 20 μM) for another 24 hours. After OGD culture, the medium was discarded and the MTT reagent (20 μL of 5 mg/mL solution, Sigma, USA) was added. The plate was incubated for 1 hour, and the MTT reagent of each well was changed with DMSO (150 μL) to dissolve the insoluble purple substance. Next, the plate was incubated at room temperature for 10 minutes. The absorbance was measured at 570 nm using a microplate reader (Varioskan Flash, Thermo, Finland).

The cell survival of neurons was determined by a lactate dehydrogenase (LDH) assay after coculture of 10000 BV2 microglia and 10000 neurons in the six-well plates in neurobasal medium with 2% B27 for 5 days at 37°C in a 5% CO₂ incubator [37]. Before coculture, the medium in the neuron culture was changed with fresh neurobasal medium with 2% B27. After OGD culture, the amount of LDH released from the neurons was measured by an LDH activity assay kit (Wanleibio, Liaoning, China) according to the manufacturer’s protocol. The absorbance was measured at 440 nm using a microplate reader.

2.5. Enzyme-Linked Immunosorbent (ELISA) Assay. The relative levels of IL-10 in supernatants of the neuron cultures of the coculture systems were measured using a mouse IL-10 ELISA Kit (Elabscience, Hangzhou, China) according to the manufacturer’s protocol. The mouse inflammation standard was used as the standard line. First, 100 μL of each sample was added to each well for 40 min. After removing the liquid, 100 μL of biotinylated detection antibody was added and the cultures were incubated for 1 hour at 37°C. Then, 100 μL of HRP conjugate was added and the cultures were incubated for another 30 min at 37°C. Finally, 90 μL of substrate reagent was added for 15 min, followed by 50 μL of stop solution. The color in each microwell changed from blue to yellow. The OD value was immediately read at 450 nm. The concentrations of inflammatory factors were measured by the standard line. The relative levels of IL-10 were compared to those of the normal group.

2.6. Immunofluorescence Assays. Cell samples were fixed in 4% paraformaldehyde for 30 min at room temperature, while 10 μm slides from the animals’ frozen brains were fixed for 24 hours after heart perfusion. The immunofluorescence experiments were similar for the cells and brain slides. After incubation in 5% bovine serum albumin (BSA) and 0.2% Triton X-100 in phosphate-buffered saline (PBS) for 1 hour at room temperature, ionized calcium-binding adapter molecule 1 (Iba-1) (1:250; Santa Cruz Biotechnology, Texas, USA), neuron-specific nuclear protein (NeuN) (1:250; Abcam, MA, USA), LDLR (1:250; Abcam, MA, USA), microtubule-associated protein (1:250; Abcam, MA, USA), and αβ (1:250; Abcam, MA, USA) were applied overnight at 4°C and the corresponding secondary antibodies (1:250; Yeasen, Shanghai, China) were applied for 1 hour at room temperature. Slides were then counterstained with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Thermo Fisher, New York, USA) for 15 min at room temperature. Immunofluorescence images were captured under a confocal microscope (Leica, Heidelberg, Germany), and the cells were counted by using Image-Pro® Plus (Version 6.0 for Windows™, National Institute of Health, Bethesda, MD, USA) [38].

2.7. Western Blotting Analysis. The expression of proteins of BV2 cells and neurons cultured in the coculture systems or brain tissues (the peri-infarct areas shown in Figure 2(a)) was analyzed by Western blotting. First, protein concentration was determined by using a BCA protein assay kit (Beyotime, Shanghai, China). The protein in each sample was separated by SDS/PAGE (Beyotime, Shanghi, China) and transferred to nitrocellulose membranes (NC, GE Healthcare Life Sciences, PA, USA). The membrane was blocked in 5% nonfat milk for 1 hour at room temperature. Then, NC membranes were incubated with hypoxia-inducible factor-1α (HIF1-α) (1:1000; Cell Signaling Technology, MA, USA), Iba-1 (1:1000; Santa Cruz Biotechnology, Shanghai, China), altered response to gravity1 (Arg1) (1:1000; Cell Signaling Technology, MA, USA), COX2 (1:1000; Cell Signaling Technology, MA, USA), pNF-κB (1:1000; Cell Signaling Technology, MA, USA), pIκBα (1:1000; Cell Signaling Technology, MA,
USA), postsynaptic density 95 (PSD95) (1:1000; Cell Signaling Technology, MA, USA), growth-associated protein 43 (GAP43) (1:1000; Wanleibio, Shenyang, China), cleaved-caspase 3 (cC3, 1:1000; Cell Signaling Technology, MA, USA), and β-actin (1:1000; Cell Signaling Technology, MA, USA) at 4°C for 16 hours. The membranes were then incubated for 1 hour with the corresponding horseradish peroxidase-conjugated IgG secondary antibody (Yeasen, Shanghai, China) at room temperature. Protein bands were visualized by using a chemiluminescence detection kit (Wanleibio, Liaoning, China).

### 2.8 Statistical Analysis.

Data in the groups were analyzed with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA 92, USA) and one-way ANOVA in SPSS 19.0 (Abacus Concepts Inc., Chicago, IL, USA). All quantitative values were expressed as the mean ± standard error of the mean (SEM). Fisher’s least significant difference (LSD) test was used for comparison between groups when homogeneity of variance was determined, while Tamhane’s T2 test was used for comparison between groups when homogeneity of variance was not determined. Spearman test was used for correlation analysis of NeuN- and Iba-1-positive neurons.

**Figure 1:** Rosuvastatin and atorvastatin suppressed the death of neurons by blocking inflammatory stimulation in the coculture systems. (a, b) Cell viability of BV2 cells for different concentrations of rosuvastatin and atorvastatin after OGD damage was measured by MTT assays. Values shown are expressed as the mean ± SEM as the ratio to the C group was assessed by one-way ANOVA followed by L test (homogeneity of variance was determined); n = 3. *p < 0.05 vs. the C group and #p < 0.05 vs. the OGD group. (c) In the coculture systems, the BV2 cells in the upper wells were carefully placed on 6-well transwell plates and cocultured with neurons in the bottom wells. (d) Relative LDH levels in neurons cocultured with BV2 microglia were determined by LDH assays. (e, f) IL-10 expression in both BV2 cell culture supernatants and neuron culture supernatants was determined by ELISA. (b, c) Values shown are expressed as the mean ± SEM as the ratio to the C group was assessed by one-way ANOVA followed by LSD test (homogeneity of variance was determined), except that the expression of IL-10 of BV2 between-group differences was assessed by one-way ANOVA followed by Tamhane’s T2 test (homogeneity of variance was not determined); n = 4. *p < 0.05 vs. the C group, **p < 0.01 vs. the C group, #p < 0.05 vs. the OGD group, ##p < 0.05 vs. the OGD group, and &&&p < 0.05 vs. the OGD group + R.
3. Results

3.1. Rosuvastatin and Atorvastatin Reduced the Number of Microglia and the Decrease in Neurons in MCAO Rats. Microglia are the principal immune cells of the brain [39] and are usually marked by Iba-1, an inflammation-associated Ca²⁺-binding protein produced from microglia [40]. The peri-infarct areas (Figure 2(a), the area of infarction is shown in white in the left cerebral cortex with TTC staining and the periphery of the ischemic area marked by the line was defined as the peri-infarct area). (b) HIF1-α and Iba-1 were determined in the ischemic cerebral cortex by Western blotting using respective antibodies. Quantified HIF1-α and Iba-1 are expressed as ratios to the sham group. Values shown are expressed as the mean ± SEM, which were assessed by one-way ANOVA followed by LSD test (homogeneity of variance was determined); n = 5. *p < 0.05 vs. the sham group and #p < 0.05 vs. the MCAO group.
suggested that hypoxia is the potential stress for Iba-1 increasing.
NeuN is a specific nuclear protein marker of neurons. The NeuN-positive cells in the peripheral area also showed similar patterns. The NeuN-positive cells significantly reduced in the MCAO group (9.64 ± 1.04 × 10⁴ cells/mm³) as compared to the sham group (19.74 ± 0.33 × 10⁴ cells/mm³) (**p < 0.01), and three days of HMG-CoA pretreatment reversed the death of neurons induced by ischemic damage (16.36 ± 0.33 × 10⁴ cells/mm³ in MCAO + R; 16.6 ± 0.52 × 10⁴ cells/mm³ in MCAO + A, Figure 3, #p < 0.05, **p < 0.01). Meanwhile, the number of Iba-1-positive cells was significantly increased, which might impose further inflammatory injury (0.28 ± 0.04 × 10⁴ cells/mm³, &&&p < 0.05) of the MCAO group compared with the sham group (3.10 ± 0.20 × 10⁴ cells/mm³, Figure 1(b)) and three days of HMG-CoA pretreatment reversed the death of neurons induced by ischemic damage (1.30 ± 0.12 × 10⁴ cells/mm³ in MCAO + R; 1.88 ± 0.29 × 10⁴ cells/mm³ in MCAO + A, Figure 3, ***p < 0.05, >>>p < 0.05). By Spearman correlation analysis, there was a negative correlation between the two positive cell numbers (correlation coefficient = −0.788, p < 0.001). Therefore, rosuvastatin and atorvastatin attenuated neuronal death related to the hypoxia-induced microglia activation in MCAO rats.

3.2. Rosuvastatin and Atorvastatin Suppressed the Death of Neurons Caused by OGD-Induced BV2 Microglial Damage. To further identify the mechanism of the neuroprotective effect of the HMG-CoA reductase inhibitor, an in vitro experiment was designed. First, it was found that rosuvastatin and atorvastatin exerted protection in OGD-damaged BV2 cells compared with control cells and the most appropriate concentrations were 5 μM rosuvastatin, which significantly increased cell viability in the ischemic condition (87.04 ± 6.98% vs. 64.86 ± 9.57% in the OGD group), and 1 μM atorvastatin, which significantly increased cell viability in the ischemic condition (78.10 ± 4.40% vs. 67.52 ± 9.64% in the OGD group) in vitro (Figures 1(a) and 1(b), p < 0.05). It was observed that the hypoxic BV2 cells induced by OGD were neurotoxic to the primary neurons in the coculture systems (Figures 1(c) and 1(d), p < 0.05), which revealed that microglia had the ability to release some micromolecules that passed through the membrane of the transwell plate and contributed to neuronal injury after hypoxic stimulation. However, rosuvastatin and atorvastatin pretreatment reversed the BV2-induced neurotoxicity and protected neurons by blocking this pathway. As brain recovery and brain damage depend on the balance of proinflammation and anti-inflammation after ischemic stroke, it is necessary to determine the inflammatory cytokines involved in statin therapy. To explore whether HMG-CoA...
3.3. Rosuvastatin and Atorvastatin Prevented Neuronal Damage by Blocking Inflammatory Stimulation in Coculture Systems. Studies showed that hypoxia can enhance the expression of HIF-1α in microglia and cause microglial activation on inflammation [41, 42]. During hypoxic HIF-1α binding to the hypoxic responsive element (HRE), the expression of NF-κB in microglia is induced [43], to exaggerate inflammatory response by microglia and provoke excessive secretion of proinflammatory cytokines including IL-1β and TNF-α [44]. As shown in Figures 4(a) and 4(b), the phenotype of BV2 cells was assessed by Western blotting. Herein, it was the expression of the marker of protective microglia Arg1 [45], compared with the increase of the HIF-1α level of OGD-treated BV2 cells, that significantly increased (**p < 0.001 vs. C, #p < 0.05 vs. OGD, and #&p < 0.05 vs. OGD + R) while the Arg1/iba1 level was significantly increased by the rosuvastatin and atorvastatin treatment (**p < 0.05 vs. C, #p < 0.05 vs. OGD, and #&p < 0.05 vs. OGD + R, Figure 4(c)). Furthermore, we sought to elucidate the protective mechanism of the HMG-CoA reductase inhibitors and analyze the levels of pNF-κB, pIκBα, and their downstream responsive inflammatory factors, such as TNF-α, IL-1β, and COX2. The NF-κB signaling pathway regulates both inflammation and apoptosis in cerebro sclerosis. As expected, OGD-induced BV2 microglia exhibited significantly increased expression of inflammatory cytokines such as TNF-α and COX2 (Figures 4(d)–4(g), ***p < 0.001 vs. C, **p < 0.01 vs. C, ###p < 0.001 vs. OGD, #&p < 0.05 vs. OGD + R; IL-1β exhibited a similar, nonsignificant trend), as well as enhanced activation of pIκBα and pNF-κB, which could be significantly decreased by rosuvastatin and atorvastatin treatment (Figures 5(h)–5(j), ***p < 0.001 vs. C, **p < 0.01 vs. C, ###p < 0.001 vs. OGD, #p < 0.05 vs. OGD, and &kp < 0.001 vs. OGD + R). Therefore, HMG-CoA reductase inhibitors prevent microglial activation-induced neuronal damage by blocking the pIκBα/pNF-κB signaling pathway and decreasing downstream inflammatory cytokines such as TNF-α, IL-1β, and COX2. Rosuvastatin, compared with atorvastatin, significantly reduced NF-κB and IκBα phosphorylation for TNF-α reduction and Arg1 promotion under OGD condition.

3.4. Rosuvastatin and Atorvastatin Increased LDLR Expression in Hypoxic BV2 Cells. LDLR is expressed in the brain, especially in microglia. The levels of LDLR down-regulation will lead to the increase of circulating LDL and neuroinflammation in Alzheimer’s disease models, while the potential targets of statins in ischemic stroke, the decrease of LDLR could be inhibited by statin treatment [24]. Herein, Western blot will be used to identify whether LDLR involved in the pathway of microglia activity induced neuron damage. As expected, the LDLR level was significantly decreased in OGD-induced BV2 cells compared with control cells (**p < 0.01, **p < 0.01, and #p < 0.05), while rosuvastatin and atorvastatin upregulated the expression of LDLRs (###p < 0.001, #p < 0.01), which may activate subsequent anti-inflammatory and neuroprotective effects (Figures 5(a) and 5(b), p < 0.05). Meanwhile, DAPI staining of cells was intact in the control group; OGD and reperfusion (OGD) caused aggravation of apoptosis and karyopyknosis, forming a number of particle spots in nuclei, while rosuvastatin and atorvastatin reduced particle spots in the OGD + R and OGD + A groups [46].

3.5. Rosuvastatin and Atorvastatin Exert Neuroprotective Effects against OGD Damage by Decreasing Aβ Accumulation in Neurons. LDLRs contribute in Aβ clearance and inhibit neuronal apoptosis in vascular and neurodegenerative diseases, further leading to neurotoxicity by proinflammation, apoptosis, and synaptic injury pathways [29]. It is also known that proinflammatory cytokines secreted by microglia promote cognitive deficits in aged people and Alzheimer’s disease (AD) patients [44, 47]. In addition, OGD-induced Aβ via the activation of the NF-kB pathway could be detected by immunolabeling [38]. To investigate the role of Aβ in mediating the neuroprotective effect of HMG-CoA reductase inhibitors against OGD damage, we performed a study in primary neurons in vitro, and for detecting the Aβ accumulation, fluorescence immunolabeling for Aβ signaling cells was available [38, 48]. We found that the increased Aβ levels in the cytoplasm of neurons induced by OGD were significantly decreased by both rosuvastatin and atorvastatin treatment (Figures 6(a) and 6(b), *p < 0.05 vs. C, #p < 0.05 vs. OGD).

3.6. Rosuvastatin and Atorvastatin Protected Neurons in the OGD Coculture System. As Aβ accumulation exerts neurotoxicity by apoptosis and synaptic injury pathways [29], we sought to determine whether antiapoptosis and anti-synaptic injury are involved in the neuroprotective pathway of HMG-CoA reductase inhibitors. PSD95 and GAP43 were considered neuronal plasticity markers, as they play crucial roles in stimulating synapse formation and reconstruction [49]. Thus, PSD95 and GAP43 were identified by Western blotting. As expected, PSD95 and GAP43 were significantly decreased in OGD cells compared with control cells, while rosuvastatin and atorvastatin significantly increased the expression of these synaptic proteins (Figures 7(a)–7(c), p < 0.05). CC3 is known as a key marker of apoptosis status [50]. Rosuvastatin and atorvastatin also exhibited antiapoptotic effects by decreasing the upregulation of CC3 levels induced by OGD damage (Figures 7(a) and 7(d), p < 0.05). Therefore, the HMG-CoA reductase inhibitors suppressed the OGD-induced LDLR downregulation and Aβ accumulation and further protected neurons from apoptosis and synaptic injury.
Figure 4: Rosuvastatin and atorvastatin prevented inflammatory activity in BV2 microglia. (a) HIF1-α, Arg1, and Iba-1 were determined in BV2 cells by Western blotting using the respective antibodies. Quantified (b) HIF1-α/β-actin and (c) Arg1/Iba-1 are expressed as ratios to the C group. (d, h) TNF-α, IL-1β, COX2, pNF-κB, and pIkBα were determined in BV2 cells by Western blotting using the respective antibodies. Quantified (e) TNF-α, (f) IL-1β, (g) COX2, (i) pNF-κB, and (k) pIkBα are expressed as ratios to the C group. Values shown are expressed as the mean ± SEM, and between-group differences were assessed by one-way ANOVA followed by LSD test (homogeneity of variance was determined), except that the expression of IL-1β between-group differences was assessed by one-way ANOVA followed by Tamhane’s T2 test (homogeneity of variance was not determined); n = 3. **p < 0.01 vs. the C group, ***p < 0.001 vs. the C group, *p < 0.05 vs. the C group, #p < 0.05 vs. the OGD group, ##p < 0.01 vs. the OGD + R group, &&&p < 0.001 vs. the OGD + R group, and &p < 0.05 vs. the OGD + R group.
FIGURE 5: Rosuvastatin and atorvastatin increased LDLR expression in hypoxic BV2 cells. (a) OGD damage decreased the level of LDLR immunoreactivity in BV2 microglia. (b) Numbers of DAPI-positive cells are expressed as ratios to the C group (%). (c) Numbers of LDLR/DAPI-positive cells are expressed as ratios to the C group. Values shown are expressed as the mean ± SEM, and between-group differences were assessed by one-way ANOVA followed by LSD test (homogeneity of variance was determined); n = 3. ***p < 0.001 vs. the C group, **p < 0.01 vs. the C group, *p < 0.05 vs. the C group, ###p < 0.001 vs. the OGD group, and ##p < 0.01 vs. the OGD group.

FIGURE 6: Rosuvastatin and atorvastatin exert neuroprotective effects against OGD damage by decreasing Aβ accumulation in neurons. (a) OGD damage resulted in increased levels of Aβ immunoreactivity in primary neurons. (b) Numbers of Aβ/β-tubulin III-positive cells are expressed as ratios to the C group. Values shown are expressed as the mean ± SEM, and between-group differences were assessed by one-way ANOVA followed by LSD test (homogeneity of variance was determined); n = 3. #p < 0.05 vs. the OGD group and *p < 0.05 vs. the C group.
4. Discussion

The available evidence has indicated that microglial activation results in the overproduction of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), which may contribute to the development and progression of postischemic neuronal damage [51, 52]. Recent randomized clinical trials have demonstrated that HMG-CoA reductase inhibitors improve short-term [10] and long-term functional outcomes of ischemic stroke patients [11, 53], although statins have been proven to be neuroprotective in cerebral ischemia in vivo [8, 54, 55] and in vitro [56, 57]. A recent study showed that the administration of HMG-CoA reductase inhibitors was beneficial for neurodegenerative disorders through cholesterol-independent and cholesterol-dependent pathways and the effects were summarized as immunomodulation by suppression of inflammation and Aβ [2, 58, 59]. Atorvastatin and rosuvastatin, which are water- and lipid-soluble statins, respectively, are the traditional and most widely used drugs for the secondary prevention of ischemic stroke. In a previous study, atorvastatin did not protect from OGD and even exaggerated apoptotic cell death induced by several toxins [13], which differs from the studies in vivo; herein, in coculture studies of microglia and neuron under OGD condition, atorvastatin might improve the animal neuron survival by the mechanisms of antilipid, anti-inflammation, and so on. However, atorvastatin might have no direct neuron protection effects. Different from atorvastatin pretreatment, rosuvastatin induces delayed preconditioning against oxygen-glucose deprivation in cultured cortical neurons by decreasing ROS production and ATP levels [14]. However, whether the secretion itself from microglia affects the neurons and the associated effect of statin are unclear. This study showed the indirect protection on neurons by reducing microglia inflammation. Herein, we investigated the effects of these two physical classes of statins and the underlying neuroprotective mechanism by which they directly inhibit microglial secretion under hypoxia in vitro.

In the ischemic brain in vivo, activated microglia initially restrict the ischemic region and increase brain damage in the very beginning; however, proinflammatory mediators produced from microglia will activate more microglia to bring many secondary complications that prolong neuron damage in an acute phase of brain ischemia [60]. We observed the peri-infarct area of cerebral ischemia rats, where microglia were marked with Iba-1, and there were decreased neurons marked with NeuN. Therefore, we suspected that microglia suffered hypoxic damage released some micromolecules that transferred to the surrounding zones to induce injury to healthy neurons. Furthermore, the expression of Iba-1 was inhibited by HMG-CoA reductase inhibitors, including rosuvastatin and atorvastatin.

To further study the mechanism of the antineuroinflammation effect, we used posthypoxia BV2 microglia cocultured with normal neurons and evaluated the status of the neurons in transwell plates. In order not to harm neurons in the first place, we chose the protective doses of statins to inhibit microglia activation in vivo—which doses always a

![Figure 7: Rosuvastatin and atorvastatin protected neurons in the OGD coculture system.](image)

(a) PSD95, GAP43, and cC3 were determined in neurons by Western blotting using the respective antibodies. Quantified (b) PSD95, (c) GAP43, and (d) cC3 protein levels are expressed as ratios to the C group. Values shown are expressed as the mean ± SEM; n = 3. #⁎⁎p < 0.01 vs. the OGD group, #⁎⁎⁎p < 0.001 vs. the OGD group, and #⁎p < 0.05 vs. the C group.
speculation is focused on the indirect neuroprotective effect by antineuroinflammation. In vitro, it is necessary and easy to control the viability, because we should choose the doses which do not harm cell viability and antineuroinflammation to further verify the speculation that the neuroprotective effect of statin pretreatment is due to the indirect function of neuroinflammation. The minimal concentration of rosuvastatin resulting in neural cell damage is >10 μM, while 0.5–10 μM rosuvastatin is effective to inhibit the activation of microglia. Similarly, the minimal concentration of atorvastatin resulting in neurite loss is more than 2 μM [63], while 0.1–1 μM atorvastatin is effective to inhibit the activation of microglia. Thus, the dose of 10 μM rosuvastatin and 1 μM atorvastatin can be optimized to a concentration that does not cause neuronal injury.

Under OGD conditions, microglia, as macrophages, differentiated into the proinflammatory microglia, rather than the anti-inflammatory ones, and secreted proinflammatory mediators and cytokines, including IL-1β, TNF-α, and COX2, while atorvastatin inhibited inflammation via the expression of TNF-α and IL-1β and activation of caspase-3 [8, 64, 65]. Herein, the statins caused reduced TNF-α, IL-1β, and COX2 levels in the supernatants of hypoxia BV2 microglia, while damage to neurons was decreased according to the detected levels of LDH and upregulated levels of anti-inflammatory cytokine IL-10. Ischemia is known to increase the deleterious effect of Aβ production for synaptic impairment by induction of IL-1β and TNF-α of microglia, contributing to early cognitive impairment in Alzheimer’s disease [66, 67]. We also observed Aβ accumulation and subsequent apoptosis and synaptic injury in neurons. PSD95 and GAP43 are related to synaptic plasticity and the expression of microtubule-associated protein 2 (MAP2) [68], while Aβ accumulation induces decreases in PSD95 and GAP43 until synaptic toxicity of neurons occurs [69]. With the administration of HMG-CoA reductase inhibitors, the levels of PSD95 and GAP43 decreased, accompanied by reduced Aβ accumulation. In addition, we observed reduced expression of CC3 following pretreatment with rosuvastatin and atorvastatin, supporting the conclusion that statins protected against hypoxia injury and, specifically, that statins increased the neuronal cell survival rate after ischemia.

Many studies have suggested that NF-κB activation is involved in ischemic brain damage [70, 71]. We and other investigators have demonstrated that the neuroprotective effects of several drugs are associated with inhibition of NF-κB activation and microglial inflammation [72, 73]. The present study showed that statins could regulate NF-κB activation and the inflammatory response of microglia to cause a proinflammation response in neurons. NF-κB transcription factors are usually present in the cytosol in an inactive state complexed with inhibitory IκB proteins; activation occurs via phosphorylation of IκBα at Ser32 and Ser36 followed by proteasome-mediated degradation, which results in the release and nuclear translocation of active NF-κB in activated microglia. However, rosuvastatin and atorvastatin might prohibit the activation of IκBα to inhibit the ischemia-induced activation of NF-κB, and thus, the expression of proinflammatory mediators and cytokines, including IL-1β, TNF-α, and COX2, was inhibited. Parallel with the decrease in inflammation, the enhanced expression of LDLR in microglia was prevented by both atorvastatin and rosuvastatin. Statins are cholesterol-lowering drugs and react in a complex manner with LDLRs, and many studies have shown that LDLRs decrease circulating LDL levels and prevent neuroinflammation in Alzheimer’s disease models [21, 23]. Therefore,
LDLRs might be regulated in microglia activation by both atorvastatin and rosuvastatin in ischemic stroke [74].

There were some limitations of the current study. BV2 cells are the best useful model to study microglia but also have many limitations, including different phenotypic, functional, and transcriptomic differences compared to primary microglia and even more with in vivo microglia; so, further studies should be validated in vivo at the future. Microglial secretion that caused morphological damage to the surrounding normal neurons should be verified by animal experiments. Furthermore, all secreted factors, in addition to the IL-1β, TNF-α, and COX2 cytokines, such as exosomes and microvesicles should be detected by microdialysis technology and proteomics analyses in vivo, which calls for further studies.

5. Conclusion

In summary, our study concluded that the proinflammatory mediators released from posts ischemia damage could cause damage to normal neurons, while HMG-CoA reductase inhibitors prevented neuronal apoptosis and synaptic injury by inactivating microglia. The underlying mechanism is that HMG-CoA reductase inhibitors prevent Aβ accumulation-induced apoptosis and synaptic injury in neurons by ameliorating the LDLR downregulation induced by OGD damage in microglia, suppressing microglia activity by blocking the pIkx-Ba/pNF-kB signaling pathway and decreasing downstream inflammatory cytokines such as TNF-α, IL-1β, and COX2 and upregulating the anti-inflammatory cytokine IL-10 (Figure 8).

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Dan Lu and Anding Xu conceived and designed the study. Lingling Shen and Jiankun Zang performed the cell and animal experiments. Dan Lu performed the statistical analysis. Dan Lu, Lingling Shen, and Hongcheng Mai finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81671167, 81671148, and 81801150), the Science and Technology Planning Project of Guangdong Province, China (no. 2017A020215049), the Natural Science Foundation of Guangdong Province, China (no. 2018A0303130182), the Guangzhou Science and Technology Program key projects of China (no. 2014Y2-00505), and the Science and Technology Program of Guangzhou, China (no. 201508020004).

References

[1] E. C. Jauch, J. L. Saver, Adams HP Jr et al., “Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 44, no. 3, pp. 870–947, 2013.

[2] A. Moretti, F. Ferrari, and R. F. Villa, “Neuroprotection for ischaemic stroke: current status and challenges,” Pharmacology & Therapeutics, vol. 146, pp. 23–34, 2015.

[3] Y. Wang, M. Liu, and C. Pu, “2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack,” International Journal of Stroke, vol. 12, no. 3, pp. 302–320, 2017.

[4] Y. Chen, S. J. Won, Y. Xu, and R. A. Swanson, “Targeting microglial activation in stroke therapy: pharmacological tools and gender effects,” Current Medicinal Chemistry, vol. 21, no. 19, pp. 2146–2155, 2014.

[5] G. Stoll, S. Jander, and M. Schroeter, “Inflammation and glial responses in ischemic brain lesions,” Progress in Neurobiology, vol. 56, no. 2, pp. 149–171, 1998.

[6] W. Y. Hwong, Z. Abdul Aziz, N. N. Sidek et al., “Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry,” BMC Neurology, vol. 17, no. 1, p. 203, 2017.

[7] J. M. Griffin, D. Kho, E. S. Graham, L. F. B. Nicholson, and S. J. O’Carroll, “Statins inhibit fibrillary β-amyloid induced inflammation in a model of the human blood brain barrier,” PLoS One, vol. 11, no. 6, article e0157483, 2016.

[8] L. Simani, N. Naderi, F. Khodagholi, M. Mehrpour, and S. Nasoohi, “Association of long-term atorvastatin with escalated stroke-induced neuroinflammation in rats,” Journal of Molecular Neuroscience, vol. 61, no. 1, pp. 32–41, 2016.

[9] L. García-Bonilla, M. Campos, D. Giralt et al., “Evidence for the efficacy of statins in animal stroke models: a meta-analysis,” Journal of Neurochemistry, vol. 122, no. 2, pp. 233–243, 2012.

[10] J. X. Fang, E. Q. Wang, W. Wang, Y. Liu, and G. Cheng, “The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review,” Internal and Emergency Medicine, vol. 12, no. 5, pp. 679–687, 2017.

[11] J. Kim, H. S. Lee, C. M. Nam, and J. H. Heo, “Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke,” Stroke, vol. 48, no. 10, pp. 2723–2730, 2017.

[12] P. Kelly and S. Prabhakaran, “Statins for neuroprotection after acute ischemic stroke: ASSORTed results but more trials needed,” Stroke, vol. 48, no. 11, pp. 2922–2923, 2017.

[13] J. Bösel, F. Gandor, C. Harms et al., “Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons,” Journal of Neurochemistry, vol. 92, no. 6, pp. 1386–1398, 2005.

[14] F. Domoki, B. Kis, T. Gáspar et al., “Rosuvastatin induces delayed preconditioning against oxygen-glucose deprivation in cultured cortical neurons,” American Journal of Physiology-Cell Physiology, vol. 296, no. 1, pp. C97–C105, 2009.
[15] R. M. Ransohoff, "Neuroinflammation: surprises from the sanitary engineers," Nature, vol. 532, no. 7598, pp. 185-186, 2016.

[16] J. Yang, Y. Zhao, L. Zhang et al., "RIPK3/MLKL-mediated neuronal necroptosis modulates the M1/M2 polarization of microglia/macrophages in the ischemic cortex," Cereb Cortex, vol. 28, no. 7, pp. 2622–2635, 2018.

[17] H. Chen, W. Lin, Y. Zhang et al., "IL-10 promotes neurite outgrowth and synapse formation in cultured cortical neurons after the oxygen-glucose deprivation via JAK1/STAT3 pathway," Scientific Reports, vol. 6, no. 1, article 30459, 2016.

[18] M. Kanazawa, I. Ninomiya, M. Hatakeyama, T. Takahashi, and T. Shimohata, "Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke," International Journal of Molecular Sciences, vol. 18, no. 10, article 2135, 2017.

[19] L. Yao, X. Gu, Q. Song et al., "Reduced cognitive function, increased blood-brain-barrier transport and inflammatory responses, and altered brain metabolites in LDLr−/−and C57BL/6 mice fed a Western diet," PLoS One, vol. 13, no. 2, article e0191909, 2018.

[20] L. Hirumangalakudi, A. Prakasham, R. Zhang et al., "High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice," Journal of Neurochemistry, vol. 106, no. 1, pp. 475–485, 2008.

[21] L. Yao, X. Gu, Q. Song et al., "Nanoformulated alpha-mangostin ameliorates Alzheimer’s disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance," Journal of Controlled Release, vol. 226, pp. 1–14, 2016.

[22] D. W. Desmond, J. T. Moroney, M. Sano, and Y. Stern, "Incidence of dementia after ischemic stroke: results of a longitudinal study," Stroke, vol. 33, no. 9, pp. 2254–2262, 2002.

[23] M. Grau-Olivares and A. Arboix, "Mild cognitive impairment in stroke patients with ischemic cerebral small-vessel disease: a forerunner of vascular dementia?", Expert Review of Neurotherapeutics, vol. 9, no. 8, pp. 1201–1217, 2009.

[24] J. A. Schneider and D. A. Bennett, "Where vascular meets neurodegenerative disease," Stroke, vol. 41, 10, Supplement 1, pp. S144–S146, 2010.

[25] A. Popa-Wagner, A. M. Buga, B. Popescu, and D. Muresanu, "Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle," Journal of Neural Transmission, vol. 122, Supplement 1, pp. 47–54, 2013.

[26] C. Iadecola and J. Anrather, "The immunology of stroke: from mechanisms to translation," Nature Medicine, vol. 17, no. 7, pp. 796–808, 2011.

[27] M. Guglielmo, M. Aragno, R. Autelli et al., "The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1α," Journal of Neurochemistry, vol. 108, no. 4, pp. 1045–1056, 2009.

[28] P. Sun, G. Esteban, T. Inokuchi et al., "Protective effect of the multitarget compound DPH-4 on human SSAA/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia," British Journal of Pharmacology, vol. 172, no. 22, pp. 5390–5402, 2015.

[29] R. M. Clarke, F. O’Connell, A. Lyons, and M. A. Lynch, "The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-β1-42 in the rat hippocampus in vivo," Neuropharmacology, vol. 52, no. 1, pp. 136–145, 2007.

[30] G. Tsivgoulis, A. H. Katsanos, V. K. Sharma et al., "Statin pre-treatment is associated with better outcomes in large artery atherosclerotic stroke," Neurology, vol. 86, no. 12, pp. 1103–1111, 2016.

[31] H. Zhu, Y. Zhang, Z. Shi et al., "The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the P38/AKT and MAPK pathways," Scientific Reports, vol. 6, no. 1, article 26859, 2016.

[32] M. R. Clarke, F. O’Connell, A. Lyons, and M. A. Lynch, "The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-β1-42 in the rat hippocampus in vivo," Neuropharmacology, vol. 52, no. 1, pp. 136–145, 2007.

[33] Z. Li, Y. Zeng, X. Chen et al., "Neural stem cells transplanted to the subretinal space of rd1 mice delay retinal degeneration by suppressing microglia activation," Cytotherapy, vol. 18, no. 6, pp. 771–784, 2016.

[34] T. Zhang, H. Wang, Q. Li, J. Huang, and X. Sun, "Modulating autophagy affects neuroamyloidogenesis in an in vitro ischemic stroke model," Neuroscience, vol. 263, pp. 130–137, 2014.

[35] A. McDonough and J. R. Weinstein, "Correction to: neuroimmune response in ischemic preconditioning," Neurotherapeutics, vol. 15, no. 2, pp. 511–524, 2017.

[36] D. Ito, Y. Imai, K. Ohawa, N. Nakajima, Y. Fukuuchi, and M. Take-oka, "Gusaric activates Bβ40/42 in the rat hippocampus in vivo," British Journal of Pharmacology, vol. 108, no. 4, pp. 1045–1056, 2009.

[37] T. Shimohata, "Microglia and monocytes/macrophages polar-ization reveal novel therapeutic mechanism against stroke," International Journal of Molecular Sciences, vol. 18, no. 10, article 2135, 2017.
[45] B. Xiang, C. Xiao, T. Shen, and X. Li, “Anti-inflammatory effects of anisalcohol on lipopolysaccharide-stimulated BV2 microglia via selective modulation of microglia polarization and down-regulation of NF-κB p65 and JNK activation,” Molecular Immunology, vol. 95, pp. 39–46, 2018.

[46] Y. Sun, W. Zhu, S. Zhou, Z. Wang, X. Chen, and L. Jia, “Exploring the model of PC12 apoptosis induced by OGSD/R through in vitro experiments,” Oncotarget, vol. 8, no. 52, pp. 90176–90184, 2017.

[47] M. T. Heneka, M. K. O’Banion, D. Terwel, and M. P. Kummer, “Neuroinflammatory processes in Alzheimer’s disease,” Journal of Neural Transmission, vol. 117, no. 8, pp. 919–947, 2010.

[48] J. R. Clarke, N. M. Lyra e Silva, C. P. Figueiredo et al., “Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation,” EMBO Molecular Medicine, vol. 7, no. 2, pp. 190–210, 2015.

[49] J. Ma, Z. Zhang, Y. Su et al., “Magnetic stimulation modulates structural synaptic plasticity and regulates BDNF–TrkB signal pathway in cultured hippocampal neurons,” Neurochemistry International, vol. 62, no. 1, pp. 84–91, 2013.

[50] Y. Liu, H. Yang, G. Jia et al., “The synergistic neuroprotective effects of combined rosuvastatin and resveratrol pretreatment against cerebral ischemia/reperfusion injury,” Journal of Stroke and Cerebrovascular Diseases, vol. 27, no. 6, pp. 1697–1704, 2018.

[51] H. M. Gao and J. S. Hong, “Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,” Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008.

[52] L. Zhang, L. Y. Dong, Y. J. Li, Z. Hong, and W. S. Wei, “The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor,” Journal of Neuroinflammation, vol. 9, no. 1, p. 211, 2012.

[53] X. Yi, Z. Han, C. Wang, Q. Zhou, and J. Lin, “Statin and aspirin pretreatment are associated with lower neurological deterioration and platelet activity in patients with acute ischemic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 26, no. 2, pp. 352–359, 2017.

[54] J. Yang, Y. Pan, X. Li, and X. Wang, “Atorvastatin attenuates cognitive deficits through Akt1/caspase-3 signaling pathway in ischemic stroke,” Brain Research, vol. 1629, pp. 231–239, 2015.

[55] A. L. Rodriguez-Perea, J. Gutierrez-Vargas, G. P. Cardona-Gómez, C. J. M. Guarin, M. Rojas, and P. A. V. Hernandez, “Atorvastatin modulates regulatory T cells and attenuates cerebral damage in a model of transient middle cerebral artery occlusion in rats,” Journal of Neuroimmune Pharmacology, vol. 12, no. 1, pp. 152–162, 2016.

[56] J. H. Lim, J. C. Lee, Y. H. Lee et al., “Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal,” Journal of Neurochemistry, vol. 97, no. 1, pp. 140–150, 2006.

[57] H. M. Sohn, J. Y. Hwang, J. H. Ryu et al., “Simvastatin protects ischemic spinal cord injury from cell death and cytotoxicity through decreasing oxidative stress: in vitro primary cultured rat spinal cord model under oxygen and glucose deprivation/reoxygenation conditions,” Journal of Orthopaedic Surgery and Research, vol. 12, no. 1, p. 36, 2017.

[58] K. S. Hong and J. S. Lee, “Statins in acute ischemic stroke: a systematic review,” Journal of Stroke, vol. 17, no. 3, pp. 282–301, 2015.
deficits following systemic immune challenge,” *Journal of Neuroinflammation*, vol. 15, no. 1, p. 100, 2018.

[73] D. Lu, L. H. Zhu, X. M. Shu et al., “Ginsenoside Rg1 relieves tert-Butyl hydroperoxide-induced cell impairment in mouse microglial BV2 cells,” *J Asian Nat Prod Res*, vol. 17, no. 9, pp. 930–945, 2015.

[74] C. P. Lin, P. H. Huang, C. F. Lai, J. W. Chen, S. J. Lin, and J. S. Chen, “Simvastatin attenuates oxidative stress, NF-κB activation, and artery calcification in LDLR−/− mice fed with high fat diet via down-regulation of tumor necrosis factor-α and TNF receptor 1,” *PLoS One*, vol. 10, no. 12, article e0143686, 2015.